Literature DB >> 15598038

Novel indirubin derivatives, promising anti-tumor agents inhibiting cyclin-dependent kinases.

K H Merz1, S Schwahn, F Hippe, S Mühlbeyer, S Jakobs, G Eisenbrand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15598038     DOI： 10.5414/cpp42656

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  4 in total

1.  Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.

Authors:  Konstantina Vougogiannopoulou; Yoan Ferandin; Karima Bettayeb; Vassilios Myrianthopoulos; Olivier Lozach; Yunzhen Fan; Carl Hirschie Johnson; Prokopios Magiatis; Alexios-Leandros Skaltsounis; Emmanuel Mikros; Laurent Meijer
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

2.  The different effects of indirubin on effector and CD4+CD25+ regulatory T cells in mice: potential implication for the treatment of autoimmune diseases.

Authors:  Aijun Zhang; Yanyan Qu; Baojun Zhang; Lianjun Zhang; Chun Zeng; Jianxia Peng; Xuebin Ji; Ming Hou; Yong Zhao
Journal:  J Mol Med (Berl)       Date:  2007-07-17       Impact factor: 4.599

3.  Sequencing and Analysis of Strobilanthes cusia (Nees) Kuntze Chloroplast Genome Revealed the Rare Simultaneous Contraction and Expansion of the Inverted Repeat Region in Angiosperm.

Authors:  Haimei Chen; Junjie Shao; Hui Zhang; Mei Jiang; Linfang Huang; Zhao Zhang; Dan Yang; Molly He; Mostafa Ronaghi; Xi Luo; Botao Sun; Wuwei Wu; Chang Liu
Journal:  Front Plant Sci       Date:  2018-03-14       Impact factor: 5.753

Review 4.  Role of STAT3 in cancer metastasis and translational advances.

Authors:  Mohammad Zahid Kamran; Prachi Patil; Rajiv P Gude
Journal:  Biomed Res Int       Date:  2013-10-02       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.